vTv Therapeutics Inc. (NASDAQ:VTVT) Short Interest Update

vTv Therapeutics Inc. (NASDAQ:VTVT) was the recipient of a significant decline in short interest in February. As of February 28th, there was short interest totalling 24,100 shares, a decline of 13.6% from the February 13th total of 27,900 shares. Currently, 1.6% of the company’s stock are short sold. Based on an average trading volume of 13,300 shares, the days-to-cover ratio is currently 1.8 days.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in VTVT. JPMorgan Chase & Co. purchased a new stake in vTv Therapeutics in the 4th quarter valued at about $25,000. Geode Capital Management LLC grew its holdings in shares of vTv Therapeutics by 12.9% in the fourth quarter. Geode Capital Management LLC now owns 11,634 shares of the biotechnology company’s stock valued at $158,000 after acquiring an additional 1,327 shares in the last quarter. Finally, FMR LLC purchased a new stake in shares of vTv Therapeutics during the third quarter valued at approximately $2,402,000. 17.51% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on VTVT shares. Alliance Global Partners assumed coverage on vTv Therapeutics in a report on Monday, December 9th. They issued a “buy” rating and a $35.00 target price on the stock. StockNews.com started coverage on shares of vTv Therapeutics in a research report on Wednesday. They set a “sell” rating for the company.

vTv Therapeutics Stock Down 3.6 %

VTVT stock opened at $17.60 on Friday. The firm has a market capitalization of $56.14 million, a PE ratio of -3.89 and a beta of 1.07. vTv Therapeutics has a twelve month low of $12.12 and a twelve month high of $30.99. The stock’s 50 day moving average is $16.92 and its 200-day moving average is $15.44.

vTv Therapeutics (NASDAQ:VTVT) last issued its quarterly earnings data on Thursday, March 20th. The biotechnology company reported ($0.55) earnings per share for the quarter, beating the consensus estimate of ($0.87) by $0.32. The company had revenue of $0.02 million for the quarter.

vTv Therapeutics Company Profile

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.